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Abstract
Borderline ovarian tumors are rare low malignant potential neoplasms characterized by the absence of stromal
invasion, whose main prognostic factors are stage and type of peritoneal implants. The latter are defined as
invasive when cell proliferation invades the underlying tissue (peritoneal surface, omentum and intestinal wall),
or noninvasive. It is still unknown if these implants are metastatic spread from the primary ovarian mass or a
neoplastic transformation de novo of the peritoneal surface. Mitochondrial DNA sequencing was performed to
assess clonality in eight patients presenting both borderline ovarian tumors and implants. In 37.5% of the cases,
the same mitochondrial DNA mutation was present in both borderline ovarian tumors and the peritoneal implant,
being this evidence that implants may arise as a consequence of a spread from a single ovarian site.
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Findings
Background
Borderline ovarian tumors (BOTs) represent a heteroge-
neous group of noninvasive neoplasms of low malignant
potential. They comprise about 15–20% of all epithelial
ovarian malignancies [1] and are usually diagnosed as
being limited to the ovary. The 10-year survival rate for
women with stage I BOT is around 70%, caused by sub-
sequently recurrent disease or progression to invasive
carcinoma [2, 3]. Standard treatment is hysterectomy
with bilateral adnexectomy and multiple peritoneal
biopsies. In young patients conservative treatment is an
option and they may undergo surgery limited to a unilat-
eral salpingo-ovariectomy with multiple biopsies [4].
Serous histotype represents 65% of all the BOTs [5],
about 35% of which can occur in association with serous
lesions involving the peritoneum, i.e. implants, defined
as either invasive or noninvasive depending on their
microscopic appearance. Invasive implants are found in
a lower number of patients (22%) compared to noninva-
sive ones (78%) [5], and the survival rate is around 66%
after a mean follow-up of 7.4 years, compared to 95%
for patients with noninvasive implants [6]. A study on
80 cases of serous BOTs with noninvasive implants
showed that after a follow-up of 15 years, 44% of pa-
tients presented recurrences and 25% died of disease [7].
The pathological stage and sub-classification of extra-
ovarian disease into invasive and noninvasive im-
plants, together with the presence of postoperative
macroscopic residual masses, currently appears to be
the major predictor not only for recurrence, but also
for survival [8, 9].
In the last years, clonality studies have attempted to
elucidate whether multiple tumor nodules arise as a re-
sult of a spread from a single ovarian site or whether
such deposits are polyclonal, representing independent
primary tumors, with discordant results [10, 11].
BOT patients recurrence and survival change substan-
tially depending on whether a peritoneal implant arises
or not. Since women with BOT and peritoneal lesions
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usually have a good prognosis, the latter are classified as
implants instead of metastases. These masses are consid-
ered as an extra-ovarian spread of the primary tumor
[11], but several studies highlight their differences with
the latter, considering implants as independent masses
of polyclonal origin [10]. In spite of this still open di-
lemma, approaches for discrimination between the
monoclonal or polyclonal nature of peritoneal implants
are still lacking. Mitochondrial DNA sequencing was re-
cently shown to be a robust tool to define clonality in
simultaneously detected tumors of the female genital
tract [12, 13] as it is virtually impossible that the same
tumor-specific mutation may arise in two independent
neoplasms. We here apply such technique to BOTs and
their implants.
Results
We performed whole mitochondrial DNA sequencing
on eight patients presenting with serous BOTs and im-
plants (Table 1), after collection of informed consent
within the frame of the Mitochondria in Progression of
Endometrial and Ovarian cancer - MiPEO study, ap-
proved by the local ethical committee. An alpha-
numeric code (from B1 to B8) was assigned to the cases
to maintain anonymity.
Three out of eight patients underwent complete sta-
ging and 5/8 (62.5%) fertility sparing treatment following
their wish to become pregnant. Based on histopatho-
logical analyses, all samples were serous BOTs, 2 of
whom with one small focus of intraepithelial cancer in
the ovarian cyst. Noninvasive implants were diagnosed
in 7/8 cases (87.5%), only one patient presenting with an
invasive implant (12.5%), and relapsing after 30 months
from the first surgery. Recurrences were observed only
in patients with fertility sparing treatment (4/5–80%).
Three out of seven patients (42.8%) diagnosed with non-
invasive implants presented relapse after their first sur-
gery (Table 1). All patients were alive and free of disease
at the latest follow up.
The entire mitochondrial DNA sequence was obtained
from all 16 single BOT and implant samples [14] and
variants carefully filtered for pathogenicity through
MToolBox [15, 16]. Detailed materials and methods are
available as Additional file 1. For all eight patients, DNA
extracted from unaffected tissue was used to detect
tumor-specific and non-tumor-specific variants. Se-
quences of B1-B8 samples, including matched non-
tumor sequences, were submitted to the public human
mitochondrial database HmtDB [17] and a list of speci-
mens and HmtDB identifiers is reported in Additional
file 2. Overall, 7 tumor-specific variants in coding genes
were found in 4/8 patients (50%) (Table 2).
In patient B1, the m.15570T > C/(MT-CYB) was found
in both BOT and implant (Fig. 1a) whereas the
m.4810G > A/(MT-ND2) was found only in BOT. B2
carried the mutations m.3428G > A/(MT-ND1) and
m.15219insA/(MT-CYB) only in BOT. In patient B3, we
found the m.11984 T > C/(MT-ND4) in both BOT and
implant (Fig. 1b). In patient B4, the m.15449 T > C/(MT-
CYB) was found in both BOT and implant (Fig. 1c)
whereas the m.3352G > A/(MT-ND1) was found only in
BOT. None of the corresponding matched non-tumor
samples was shown to carry these mitochondrial DNA
mutations. All mitochondrial DNA mutations found
Table 1 Cases and histopathology
Patients Age at
diagnosis




Implant localization DFS OS
B1 35 FS Serous BOT IIB Non
invasive
Pelvic peritoneum 48 74
B2 44 CS Serous BOT IIC3 Non
invasive
Pelvic peritoneum 34 34




Pelvic peritoneum and omentum 31 31
B4 81 CS Serous BOT IIB Non
invasive
Pelvic peritoneum 120 120
B5 23 FS Serous BOT with
intraepithelial carcinoma
IIC3 Invasive Pelvic peritoneum 30 67
B6 32 FS Serous BOT IIC3 Non
invasive
Pelvic peritoneum 7 68
B7 34 FS Serous BOT IIIA Non
invasive
Pelvic peritoneum, pararectal peritoneum 13 128
B8 63 CS Serous BOT IIIA Non
invasive
Pelvic peritoneum, omentum and right
diaphragmatic peritoneum
16 16
Age, surgery, histology and FIGO stage of borderline ovarian tumors, implants type and localization, months from treatment until first relapse and months from
diagnosis to last follow up are shown
Abbreviations: FS Fertility Sparing treatment, CS Complete Staging, BOT Borderline Ovarian Tumor, DFS Disease Free Survival, OS Overall Survival
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Mutation type Amino Acid substitution Gene Variability DS
B1 m.4810G >A BOT Nonsense W114X MT-ND2 0.0 -
m.15570T >C BOT + PI Missense L275P MT-CYB 0.0 0.892
B2 m.3428G >A BOT Missense G41D MT-ND1 0.0 0.909
m.15219insA BOT Frameshift - MT-CYB 0.0 -
B3 m.11984T >C BOT + PI Missense Y409H MT-ND4 0.002 0.764
B4 m.3352G >A BOT Missense A16T MT-ND1 0.0 0.827
m.15449T >C BOT + PI Missense F235L MT-CYB 0.00642 0.088
m.16189T >C BOT + PI SNP - MT-D-loop 0.767 -
B5 m.310insC BOT Insertion - MT-D-loop 0.215 -
m.310delCC PI Deletion - MT-D-loop 0.215 -
All mitochondrial DNA mutations reported in the table are tumor-specific and heteroplasmic
Abbreviations: BOT Borderline Ovarian Tumor, PI Peritoneal Implant, SNP Single Nucleotide Polymorphism, DS Disease Score
Fig. 1 Mitochondrial DNA sequencing in BOTs and implants (a, b, c, d). Electropherograms of mitochondrial loci harboring mutations in BOT
and peritoneal implant samples. Red arrows indicate the mutated bases. (e, f) Representative dHPLC elution profiles for the in-depth investigation
of the somatic nature of mitochondrial DNA mutations m.15570 T > Y/MT-CYB in case B1 and m.11984 T > Y/MT-ND4 in case B3. Homo- and
hetero-duplexes are distinguished based on different retention times. (e) Two elution curves for T (Tumor) and I (Implant) (heteroduplex and
homoduplex) and a single elution curve for non-tumor tissue (N) and three wild-type controls are present in the analysis of m.15570 T > Y/MT-CYB in
case B1. Wild-type (black, pink and purple), N (light green), I (green), T (brown). (f) Two elution curves for T and I (heteroduplex and homoduplex) and a
single elution curve for non-tumor tissue (N) and one wild-type control are present in the analysis of m.11984 T > Y/MT-ND4 in case B3. Wild-type
(black), N (light green), I (green), T (brown)
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were heteroplasmic in the tissues, although the mutation
load may be in such cases underestimated, due to a po-
tential contamination by non-tumor cells, whose
complete exclusion from dissected tissues is virtually
impossible.
All variants featured a low variability value and, in 4/5
(80%) cases, a high score of disease indicating possible
candidate variants affecting function (Table 2) [16].
To establish the tumor specificity of the mutations
found in both BOTs and implants of the samples B1, B3
and B4 and to confirm a diagnostic efficiency of
mitochondrial DNA sequencing we performed dHPLC,
which is able to detect heteroplasmic mutations as low
as 2% [18]. Low-level germline heteroplasmy was absent
from non-tumor tissue of case B1, in which the
m.15570 T > C/(MT-CYB) was shown to be present ex-
clusively in BOT and implant samples (Fig. 1e) and ab-
sent from non-tumor tissue. We performed the same
analysis for cases B3 (Fig. 1f ) and B4 (data not shown)
revealing that the m.11984 T > C/(MT-ND4) and the m.
15449 T > C/(MT-CYB) were present exclusively in BOT
and implant samples and absent from non-tumor tis-
sues. According to these data, the germline nature of
mutations found in both BOTs and implant samples of
B1, B3 and B4 was ruled out, allowing to conclude that
tumor-specific mitochondrial DNA mutations in coding
genes were detected in 50% (4/8) of BOT at different
heteroplasmy levels. In 37.5% (3/8) of the cases, the
same mitochondrial DNA mutation was present in both
BOT and the peritoneal implant. The extremely low vari-
ability of the informative mutations found (Table 2)
strengthens the clonality hypothesis, as they are unlikely
to occur independently in different cells, as the current
variability estimates for mitochondrial genome positions
show that a great part of over 16500 nucleotides of the
human mitochondrial DNA varies among individuals
with different frequency, as it is reported in HmtDB
[17]. It is worth underlining that somatic mutations that
were found in our sample set, exclusively in the BOT
and were not shared with the peritoneal implant, by no
means rule out a clonal origin of the two neoplasms.
Mitochondrial DNA variants found only in BOTs may
indeed be subsequent to the initial clonal expansion, es-
pecially in view of their heteroplasmic nature. It is of
note that all somatic mutations in the coding sequences
presented a heteroplasmic status in the mass and a very
low variability value. They may hence be still unfixed
events, particularly since they represent highly dam-
aging genetic lesions. It is known that a certain de-
gree of mitochondrial respiratory chain activity needs
to be maintained to progress towards malignancy, and
accumulation of damaging mitochondrial DNA muta-
tions blunts tumorigenesis [19]. The occurrence of
heteroplasmic mutations may therefore be explained
by the need for a metabolic adaptation and by the
advantages they confer through the enhancement of
reactive oxygen species production associated with
tumor promotion [20, 21].
Interestingly, patients B1, B3, B4, and B6 were diag-
nosed with serous BOTs with noninvasive implants. In
sample B3, a small area of low grade intraepithelial car-
cinoma was found. Patient B1 presented a relapse after
the first surgery. Mitochondrial DNA mutations may, in
this context, concur to foster transformation of border-
line tumor cells into a more aggressive and invasive type
of cancer, making their use two-fold both in determining
clonality, hence allowing to identify metastases, and to
potentially infer a clinical behavior, thus aiding to delin-
eate the prognosis.
We last focused on the variants mapping in the D-
loop fragile spots (long C-traits), as these have been
already proposed as a marker for clonality [22, 23]. A
high frequency of the TC insertion at nucleotide position
310 was found in early stages of serous BOTs [24]. In-
deed, we found that the only positions with variants
were around nucleotides 303–309, a fragile poly-C
stretch termed D310, and 16189, as expected. Inspection
of D310 revealed that in patient B6 a heteroplasmic in-
sertion of a cytosine was present only in BOT and peri-
toneal implant, although Fluorescent PCR [19] revealed
a very low load of the insertion in the matched non-
tumor sample, thereby blunting the informative potential
in this case. Sample B5 carried a heteroplasmic insertion
of a cytosine in the BOT tissue while peritoneal implant
carried the heteroplasmic deletion of two cytosines. The
matched non-tumor sample was shown to carry no
insertions or deletions. Concerning the analysis of the
mitochondrial 16189 variant, characterized by a T > C
substitution, which produces a highly variable and fra-
gile poly-C tract, we found the T > C substitution in
BOT and implant tissue of patient B4, not occurring
in the matched non-tumoral tissue (Fig. 1d), confirm-
ing the BOT and the peritoneal implant to have the
same origin.
Overall, tumor-specific mitochondrial DNA mutations
were detected in 62.5% (5/8) of BOT at different hetero-
plasmy levels. In 37.5% of the patients, the same mito-
chondrial DNA mutation was present in both the BOT
and the peritoneal implant and was therefore inform-
ative to infer clonality.
Conclusions
Besides reporting here for the first time the occurrence
of pathogenic mitochondrial DNA mutations in BOTs,
our findings have relevant implications in the patient
management. Distinguishing between a polyclonal and a
monoclonal origin of implants is pivotal in deciding
therapeutic options. Indeed, for implants that do not
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originate from the primary tumor a peritoneal carcino-
genesis may be envisioned as a potential cause, likely to
have occurred within the Müllerian islands, whereby a
synchronous tumor to the primary BOT may develop. In
this case, removal of the primary BOT does not protect
from the formation of implants, implying that a surgical
exploration of all peritoneal surfaces and multiple periton-
eal biopsies should be mandatory and radical surgery on
reproductive organs such as contralateral ovary and uterus
plays a secondary role. On the other hand, the demonstra-
tion that implants are of a monoclonal derivation implies
that they ought to originate from a plundering of the pri-
mary tumor. Therefore, in such cases, early diagnosis and
removal of the primary tumor becomes pivotal in the pre-
vention of spread within the abdominal cavity, accounting
for the importance of molecular analyses capable of pro-
viding such a relevant proof of concept.
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